836 related articles for article (PubMed ID: 20069140)
1. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
[TBL] [Abstract][Full Text] [Related]
2. Insulin-lowering agents in the management of polycystic ovary syndrome.
De Leo V; la Marca A; Petraglia F
Endocr Rev; 2003 Oct; 24(5):633-67. PubMed ID: 14570747
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and metabolic characteristics in polycystic ovary syndrome.
Glintborg D
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
[TBL] [Abstract][Full Text] [Related]
4. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
Sharma ST; Nestler JE
Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance, polycystic ovary syndrome and metformin.
Pugeat M; Ducluzeau PH
Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome in adolescents.
Kent SC; Legro RS
Adolesc Med; 2002 Feb; 13(1):73-88, vi. PubMed ID: 11841956
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and polycystic ovary syndrome.
Galluzzo A; Amato MC; Giordano C
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
[TBL] [Abstract][Full Text] [Related]
8. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Arslanian SA; Lewy V; Danadian K; Saad R
J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Syndrome: Polycystic Ovary Syndrome.
Mortada R; Williams T
FP Essent; 2015 Aug; 435():30-42. PubMed ID: 26280343
[TBL] [Abstract][Full Text] [Related]
10. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
11. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Svendsen PF; Nilas L; Nørgaard K; Madsbad S
Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
[TBL] [Abstract][Full Text] [Related]
12. Insulin and the polycystic ovary syndrome.
Macut D; Bjekić-Macut J; Rahelić D; Doknić M
Diabetes Res Clin Pract; 2017 Aug; 130():163-170. PubMed ID: 28646699
[TBL] [Abstract][Full Text] [Related]
13. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Palomba S; Falbo A; Zullo F; Orio F
Endocr Rev; 2009 Feb; 30(1):1-50. PubMed ID: 19056992
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
16. Metformin in polycystic ovary syndrome.
Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
[TBL] [Abstract][Full Text] [Related]
17. Insulin-sensitisers in the treatment of polycystic ovary syndrome.
Teede HJ; Meyer C; Norman RJ
Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573
[TBL] [Abstract][Full Text] [Related]
18. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Franks S
Clin Endocrinol (Oxf); 2011 Feb; 74(2):148-51. PubMed ID: 21121941
[TBL] [Abstract][Full Text] [Related]
19. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
20. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Nardo LG; Rai R
Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
